OFFICER EMPLOYMENT AGREEMENTOfficer Employment Agreement • November 6th, 2017 • XOMA Corp • Pharmaceutical preparations • California
This Officer Employment Agreement (“Agreement”) between James R. Neal (“Employee”) and XOMA Corporation (“XOMA”) (collectively, the “Parties”) is effective as of August 7, 2017 (the “Agreement Effective Date”).
AMENDED AND RESTATED CHANGE OF CONTROL SEVERANCE AGREEMENTChange of Control Severance Agreement • November 6th, 2017 • XOMA Corp • Pharmaceutical preparations • California
Thomas Burns (“Employee”) and XOMA Corporation (“XOMA”) entered into a Change of Control Severance Agreement effective October 28, 2015 (the “Prior Agreement”). Employee and XOMA (collectively, the “Parties”) hereby agree to amend and restate the Prior Agreement. The terms and conditions set forth in this Amended and Restated Change of Control Severance Agreement (“Agreement”) shall become effective as of August 7, 2017 (“Agreement Effective Date”), and shall supersede and replace the terms and conditions set forth in the Prior Agreement.
IL-1 TARGET LICENSE AGREEMENT by and between XOMA (US) LLC and NOVARTIS PHARMA AGIl-1 Target License Agreement • November 6th, 2017 • XOMA Corp • Pharmaceutical preparations • New York
This IL-1 TARGET LICENSE AGREEMENT (the “Agreement”) is entered into as of the 24th day of August, 2017 (the “Effective Date”) by and between XOMA (US) LLC, a limited liability company organized under the laws of Delaware having offices at 2910 Seventh St., Berkeley, CA, USA, 94710 (“XOMA”), and Novartis Pharma AG, company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland and registered in the Commercial Register of the Canton of Basel-Stadt, Switzerland, under number CHE-106.052.527 whose registered office is at Lichtstrasse 35, CH 4056 Basel, Switzerland (“Novartis”). XOMA and Novartis are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”
XOMA CORPORATION COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • November 6th, 2017 • XOMA Corp • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE AGREEMENT (this “Agreement”) is made as of August 24, 2017 (the “Execution Date”) by and between XOMA Corporation, a Delaware corporation (the “Company”), and Novartis Pharma AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland (the “Investor”).
LICENSE AGREEMENT by and between XOMA (US) LLC and NOVARTIS PHARMA AGLicense Agreement • November 6th, 2017 • XOMA Corp • Pharmaceutical preparations • New York
This LICENSE AGREEMENT (the “Agreement”) is entered into as of the 24th day of August, 2017 (the “Effective Date”) by and between XOMA (US) LLC, a limited liability company organized under the laws of Delaware having offices at 2910 Seventh St., Berkeley, CA, USA, 94710 (“XOMA”), and Novartis Pharma AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland and registered in the Commercial Register of the Canton of Basel-Stadt, Switzerland, under number CHE-106.052.527 whose registered office is at Lichtstrasse 35, 4056 Basel, Switzerland (“Novartis”). XOMA and Novartis are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”
Amendment and Restatement to AgreementsAsset Purchase Agreement and License Agreement • November 6th, 2017 • XOMA Corp • Pharmaceutical preparations
This Amendment and Restatement (“Amendment”) to both the Asset Purchase Agreement (“APA”) and Nanotherapeutics License Agreement (“License Agreement”) is dated February 2, 2017, between XOMA Corporation (“XOMA”) and Nanotherapeutics, Inc. (“Nano”). Capitalized terms not otherwise defined in this Amendment shall have the meaning set forth in the APA and License Agreement.
NANOTHERAPEUTICS LICENSE AGREEMENT, BY AND BETWEEN XOMA (US) LLC and NANOTHERAPEUTICS, INC. March 23, 2016License Agreement • November 6th, 2017 • XOMA Corp • Pharmaceutical preparations • California
This NANOTHERAPEUTICS LICENSE AGREEMENT (this “Agreement”) is entered into as of March 23, 2016 (the “Effective Date”) by and between XOMA (US) LLC, a Delaware limited liability company (“Licensor), and Nanotherapeutics, Inc., a Delaware Corporation (“Licensee”). Each of Licensor and Licensee is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
